Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

ResMed's Study Results For Central Sleep Apnea Hold Promise

By Zacks Investment ResearchStock MarketsApr 11, 2017 04:17AM ET
www.investing.com/analysis/resmed's-study-results-for-central-sleep-apnea-hold-promise-200182315
ResMed's Study Results For Central Sleep Apnea Hold Promise
By Zacks Investment Research   |  Apr 11, 2017 04:17AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Medical device company ResMed Inc. (NYSE:RMD) recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA). According to the study, CSA patients are more responsive toward adaptive servo-ventilation (ASV) therapy when they switch from continuous positive airway pressure (CPAP) therapy.

Notably, OSA is a kind of sleep disorder in which the throat muscles relax, block the airways and stop the flow of breath during sleep. CSA is another sleep disorder in which the brain fails to transmit the ‘breathe’ signal to the muscles that control breathing during sleep.

The analysis compared compliance rates of 198,890 patients using anonymous, aggregated telemonitoring data from a U.S. positive airway pressure (PAP) therapy database. All patients in the analysis received CPAP via ResMed's AirSense 10 or ASV via ResMed's AirCurve 10 devices. In particular, three groups of patients – "CPAP-only," "ASV-only" and Switch" that started on CPAP and switched to ASV – were evaluated.

The 90-day compliance rates for the CPAP-only and ASV-only groups were 73.8% and 73.2%, respectively. In the Switch group, patients beginning on CPAP had the lowest initial compliance rate of 62.7% which improved to 76.6% after switching to ASV. Further, ASV reduced obstructive and central events.

The study quite clearly demonstrated the efficacy of ASV over CPAP. The market for CSA is gradually expanding and gaining importance over time. Currently, CSA has been linked to a wide range of diseases. Especially, this breathing disorder during sleep has been seen to develop among OSA patients who are on CPAP and have a history of ischemic stroke or have taken opioids for chronic pain.

Taking the growing significance of the global CSA market into consideration, we believe the latest development at ResMed is a strategic fit. According to a report by Markets and Markets, the sleep apnea devices market is expected to reach a worth of $6.70 billion by 2021 from $4.59 billion in 2016, growing at a CAGR of 7.8%. Thus, the company has considerable scope for expansion in this niche market.

Recent Developments

ResMed AirMini – which was recently cleared by the FDA – is expected to be launched at the end of fiscal 2017. The device is a tiny portable travel PAP with ResMed's best-in-class comfort features. AirMini is intended to be a secondary device for travel and complements the AirSense 10 platform.

The company has also launched the AirFit range of masks, such as AirFit N20 nasal mask andAirFit F20 full face mask recently. In the area of sleep help and wellness, the company is also making progress with the new joint venture called Sleep Score Labs.

Zacks Rank & Key Picks

Currently, ResMed carries a Zacks Ranks #4 (Sell). Better-ranked stocks in the broader Medical - Products space include Hill-Rom Holdings, Inc. (NYSE:HRC) , Hologic, Inc. (NASDAQ:HOLX) and ZELTIQ Aesthetics, Inc. (NASDAQ:ZLTQ) . While Hologic sports a Zacks Rank #1 (Strong Buy), Hill-Rom and ZELTIQ Aesthetics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Hill Rom gained 33.43% in the last one year compared with the S&P 500’s gain of 13.75%. The company reported a stellar four-quarter positive average earnings surprise of 3.11%.

Hologic rose 20.52% in the last one year compared with the S&P 500’s gain. Its four-quarter average earnings surprise is a positive 4.16%.

ZELTIQ Aesthetics gained 97.07% in the past one year, surpassing the S&P 500 mark. It posted a trailing four-quarter positive average earnings surprise of 12.03%.

Looking for Ideas with Even Greater Upside?

Most of Zacks’ investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>



Hologic, Inc. (HOLX): Free Stock Analysis Report

ResMed Inc. (RMD): Free Stock Analysis Report

Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report

ZELTIQ Aesthetics, Inc. (ZLTQ): Free Stock Analysis Report

Original post

Zacks Investment Research
ResMed's Study Results For Central Sleep Apnea Hold Promise
 

Related Articles

ResMed's Study Results For Central Sleep Apnea Hold Promise

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email